<DOC>
	<DOCNO>NCT02378506</DOCNO>
	<brief_summary>Open-label immunogenicity , safety efficacy study etanercept manufacture use high capacity process . Descriptive result provide however formal hypothesis test trial .</brief_summary>
	<brief_title>Study Assess Immunogenicity , Safety , Efficacy High Capacity Process Etanercept Rheumatoid Arthritis Subjects</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Moderate severe active disease presence least 4 tender joint 4 swollen joint . Either patient designee must capable administer subcutaneous injection study drug . Prior treatment etanercept . Presence active infection active untreated tuberculosis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>